Spitalul Clinic Municipal De Urgenta Timisoara

The medical center is at the forefront of research in Chronic Myeloid Leukemia, focusing on innovative treatments that enhance patient outcomes. The center's studies explore the efficacy and tolerability of novel therapeutic agents, such as asciminib, in comparison to established treatments like nilotinib.

• Comparative studies of asciminib and nilotinib
• Time to discontinuation due to adverse events
• Long-term safety assessments

Through these efforts, the center contributes significantly to the understanding of treatment tolerability and long-term safety, providing valuable insights for the management of CML.

Specializing in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, the center conducts pivotal research to improve therapeutic strategies for patients with these conditions. The focus is on evaluating the progression-free survival of combination therapies involving lisaftoclax and acalabrutinib.

• Progression-free survival analysis
• Combination therapy efficacy
• Independent radiological review

By advancing the understanding of combination therapies, the center plays a crucial role in enhancing treatment protocols and patient care in CLL/SLL.

The center is dedicated to advancing research in Philadelphia Chromosome Positive leukemias, including both chronic and acute phases. The ongoing studies aim to provide continued access to innovative treatments like asciminib, ensuring long-term safety and efficacy for patients transitioning from parent studies.

• Long-term safety of asciminib
• Access to continued treatment
• Management of Ph+ ALL

These initiatives underscore the center's commitment to improving therapeutic options and outcomes for patients with Philadelphia Chromosome Positive leukemias.